The 2021 ACR/Vasculitis Foundation guidelines recommend treatment of TAK with glucocorticoids, followed by conventional disease-modifying antirheumatic drugs, then tumor necrosis factor (TNF) inhibitors or interleukin-6 (IL-6) inhibitors.4 This evidence concerns the gene IL6 and vasculitis.